Table 2.
The summary of the methodology in the included studies.
| Author | Year | Selection criteria |
Design |
Outcome measure | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age | VAS (mm) | Cough duration (months) | Diagnosis | Blind | Crossover/Parallel | Duration of interventions at each stage | Washout period | |||
| McGarvey | 2023 | 18–80 | ≥40 | ≥12 | R/UCC | Double | Parallel | 2 weeks | – | Cough frequency (VitaloJAK cough monitor) |
| Niimi A | 2022 | 20–75 | ≥40 | ≥6 | R/UCC | Double | Crossover | 2 weeks | 2–3 weeks | LCQ, VAS, cough frequency (VitaloJAK cough monitor) |
| Niimi B | 2022 | ≥20 | – | ≥4 | R/UCC | Double | Parallel | 52 weeks | – | LCQ, cough frequency (VitaloJAK cough monitor) |
| Badri | 2022 | >18 | >2 | RCC | Double | Crossover | 2 weeks | 1–2 weeks | Cough frequency (VitaloJAK cough monitor) | |
| McGarvey | 2022 | ≥18 | ≥40 | ≥12 | R/UCC | Double | Parallel | 52 weeks | – | LCQ, VAS, cough frequency (VitaloJAK cough monitor) |
| Ludbrook | 2021 | 18–75 | ≥40 | ≥12 | R/ICC | Double | Crossover | 1 weeks | 2–3 weeks | Cough frequency (VitaloJAK cough monitor) |
| Morice | 2021 | ≥18 | ≥40 | ≥12 | RCC | Double | Crossover | 3 weeks | 3–4 weeks | LCQ, VAS, cough frequency (VitaloJAK cough monitor) |
| Abdulqawi | 2020 | ≥18 | – | – | RCC | Double | Crossover | 2 weeks | 1.5–2 h | VAS, cough frequency (VitaloJAK cough monitor) |
| Smith A | 2020 | 18–80 | ≥40 | ≥12 | R/UCC | Double | Parallel | 12 weeks | – | LCQ, VAS, cough frequency (VitaloJAK cough monitor) |
| Smith B | 2020 | – | ≥40 | ≥12 | CC | Double | Crossover | 16 days | 1–3 weeks | LCQ, VAS, cough frequency (VitaloJAK cough monitor) |
| Morice | 2019 | 18–80 | – | ≥12 | RCC | Double | Crossover | 1 day | 2 days | VAS |
| Smith | 2019 | 18–75 | – | >3 | RCC | No | Parallel | 4 weeks | – | VAS, cough frequency (VitaloJAK cough monitor) |
| Belvisi | 2017 | – | – | – | RCC | Double | Crossover | 2 weeks | 2 weeks | LCQ, VAS, cough frequency (VitaloJAK cough monitor) |
| Birring | 2017 | 18–75 | ≥40 | >2 | CC | Double | Crossover | 15 days | 2 weeks | LCQ, VAS, cough frequency (Leicester cough monitor) |
| Hodgson | 2016 | – | – | – | – | Double | Parallel | 8 weeks | – | LCQ, cough frequency |
| Abdulqawi | 2015 | – | – | >2 | RCC | Double | Crossover | 2 weeks | 2 weeks | VAS, cough frequency (VitaloJAK cough monitor) |
| Khalid | 2014 | – | – | >2 | RCC | Double | Crossover | 3 days | 4 weeks | VAS, cough frequency (VitaloJAK cough monitor) |
| Ryan | 2012 | – | – | >2 | CC | Double | Parallel | 12 weeks | – | LCQ, VAS, cough frequency (Leicester cough monitor) |
| Yousaf | 2010 | – | – | >2 | CC | Double | Parallel | 12 weeks | – | LCQ, VAS, cough frequency (Leicester cough monitor) |
Abbreviations: VAS, visual analogue score; RCC, refractory chronic cough; UCC, unexplained chronic cough; ICC, idiopathic chronic cough; CC, chronic cough.